vs
Amphastar Pharmaceuticals, Inc.（AMPH）とフォッシル・グループ（FOSL）の財務データ比較。上の社名をクリックして会社を切り替えられます
フォッシル・グループの直近四半期売上が大きい（$270.2M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.5倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs -14.8%、差は28.2%）。Amphastar Pharmaceuticals, Inc.の前年同期比売上増加率が高い（-1.8% vs -21.1%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $-22.5M）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs -11.4%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
Fossil Groupは1984年に設立されたアメリカのファッションデザイン・製造企業で、本社はテキサス州リチャードソンにあります。Fossil、Relic、Michele Watch、Skagen、Zodiac Watchesなどの自社ブランドを擁し、BMW、プーマ、アルマーニ、マイケル・コース、DKNYなど多数の有名ブランドのライセンスアクセサリーも製造しています。
AMPH vs FOSL — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $270.2M |
| 純利益 | $24.4M | $-40.0M |
| 粗利率 | 46.8% | 49.0% |
| 営業利益率 | 19.4% | -8.0% |
| 純利益率 | 13.3% | -14.8% |
| 売上前年比 | -1.8% | -21.1% |
| 純利益前年比 | -35.7% | -257.8% |
| EPS（希薄化後） | $0.51 | $-0.76 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $270.2M | ||
| Q3 25 | $191.8M | $220.4M | ||
| Q2 25 | $174.4M | $233.3M | ||
| Q1 25 | $170.5M | — | ||
| Q4 24 | $186.5M | $342.3M | ||
| Q3 24 | $191.2M | $287.8M | ||
| Q2 24 | $182.4M | $260.0M | ||
| Q1 24 | $171.8M | $254.9M |
| Q4 25 | $24.4M | $-40.0M | ||
| Q3 25 | $17.4M | $-2.1M | ||
| Q2 25 | $31.0M | $-17.9M | ||
| Q1 25 | $25.3M | — | ||
| Q4 24 | $38.0M | $-11.2M | ||
| Q3 24 | $40.4M | $-31.9M | ||
| Q2 24 | $37.9M | $-38.8M | ||
| Q1 24 | $43.2M | $-24.3M |
| Q4 25 | 46.8% | 49.0% | ||
| Q3 25 | 51.4% | 57.5% | ||
| Q2 25 | 49.6% | 61.3% | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | 53.9% | ||
| Q3 24 | 53.3% | 49.4% | ||
| Q2 24 | 52.2% | 52.6% | ||
| Q1 24 | 52.4% | 52.4% |
| Q4 25 | 19.4% | -8.0% | ||
| Q3 25 | 13.2% | 3.9% | ||
| Q2 25 | 24.2% | -2.9% | ||
| Q1 25 | 21.9% | — | ||
| Q4 24 | 24.2% | -4.8% | ||
| Q3 24 | 29.8% | -8.5% | ||
| Q2 24 | 30.3% | -13.1% | ||
| Q1 24 | 27.9% | -11.5% |
| Q4 25 | 13.3% | -14.8% | ||
| Q3 25 | 9.0% | -1.0% | ||
| Q2 25 | 17.8% | -7.7% | ||
| Q1 25 | 14.8% | — | ||
| Q4 24 | 20.4% | -3.3% | ||
| Q3 24 | 21.1% | -11.1% | ||
| Q2 24 | 20.8% | -14.9% | ||
| Q1 24 | 25.1% | -9.5% |
| Q4 25 | $0.51 | $-0.76 | ||
| Q3 25 | $0.37 | $-0.04 | ||
| Q2 25 | $0.64 | $-0.33 | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.74 | $-0.15 | ||
| Q3 24 | $0.78 | $-0.60 | ||
| Q2 24 | $0.73 | $-0.73 | ||
| Q1 24 | $0.81 | $-0.46 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $79.2M |
| 総負債低いほど良い | $608.7M | $169.1M |
| 株主資本純資産 | $788.8M | $112.6M |
| 総資産 | $1.6B | $701.0M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 1.50× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $79.2M | ||
| Q3 25 | $276.2M | $109.9M | ||
| Q2 25 | $231.8M | $78.3M | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | $123.6M | ||
| Q3 24 | $250.5M | $106.3M | ||
| Q2 24 | $217.8M | $104.9M | ||
| Q1 24 | $289.6M | $112.9M |
| Q4 25 | $608.7M | $169.1M | ||
| Q3 25 | $608.6M | $165.6M | ||
| Q2 25 | $607.7M | $167.2M | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $162.7M | ||
| Q3 24 | $596.4M | $173.4M | ||
| Q2 24 | $586.9M | $156.5M | ||
| Q1 24 | $594.0M | $202.9M |
| Q4 25 | $788.8M | $112.6M | ||
| Q3 25 | $776.7M | $150.3M | ||
| Q2 25 | $757.5M | $140.6M | ||
| Q1 25 | $751.3M | — | ||
| Q4 24 | $732.3M | $148.7M | ||
| Q3 24 | $727.7M | $164.4M | ||
| Q2 24 | $713.3M | $189.6M | ||
| Q1 24 | $672.4M | $229.1M |
| Q4 25 | $1.6B | $701.0M | ||
| Q3 25 | $1.7B | $704.5M | ||
| Q2 25 | $1.6B | $686.0M | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.6B | $763.6M | ||
| Q3 24 | $1.5B | $812.4M | ||
| Q2 24 | $1.5B | $785.7M | ||
| Q1 24 | $1.6B | $891.0M |
| Q4 25 | 0.77× | 1.50× | ||
| Q3 25 | 0.78× | 1.10× | ||
| Q2 25 | 0.80× | 1.19× | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 1.09× | ||
| Q3 24 | 0.82× | 1.06× | ||
| Q2 24 | 0.82× | 0.83× | ||
| Q1 24 | 0.88× | 0.89× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $-22.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $-22.5M |
| FCFマージンFCF / 売上 | 13.4% | -8.3% |
| 設備投資強度設備投資 / 売上 | 4.5% | 0.1% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $-46.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $-22.2M | ||
| Q3 25 | $52.6M | $9.4M | ||
| Q2 25 | $35.6M | $-60.4M | ||
| Q1 25 | $35.1M | — | ||
| Q4 24 | $29.0M | $30.5M | ||
| Q3 24 | $60.0M | $-22.8M | ||
| Q2 24 | $69.1M | $38.4M | ||
| Q1 24 | $55.3M | $622.0K |
| Q4 25 | $24.6M | $-22.5M | ||
| Q3 25 | $47.2M | $8.6M | ||
| Q2 25 | $25.0M | $-60.6M | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | $28.5M | ||
| Q3 24 | $46.2M | $-24.1M | ||
| Q2 24 | $63.1M | $36.6M | ||
| Q1 24 | $46.5M | $-1.1M |
| Q4 25 | 13.4% | -8.3% | ||
| Q3 25 | 24.6% | 3.9% | ||
| Q2 25 | 14.3% | -26.0% | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | 8.3% | ||
| Q3 24 | 24.1% | -8.4% | ||
| Q2 24 | 34.6% | 14.1% | ||
| Q1 24 | 27.1% | -0.4% |
| Q4 25 | 4.5% | 0.1% | ||
| Q3 25 | 2.8% | 0.4% | ||
| Q2 25 | 6.1% | 0.1% | ||
| Q1 25 | 6.3% | — | ||
| Q4 24 | 6.7% | 0.6% | ||
| Q3 24 | 7.2% | 0.4% | ||
| Q2 24 | 3.3% | 0.7% | ||
| Q1 24 | 5.1% | 0.7% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
FOSL
| Transferred At Point In Time | $109.7M | 41% |
| Traditional Watches | $91.3M | 34% |
| Other | $50.8M | 19% |
| Leathers | $9.5M | 4% |
| Jewelry | $4.0M | 1% |
| Smartwatches | $3.3M | 1% |
| Products Other | $1.6M | 1% |
